Company
Headquarters: Stockholm, Sweden
Employees: 192
kr16.59 Billion
SEK as of Nov. 1, 2022
US$1.49 Billion
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. It offers dermatology products under the Decubal, Fungobase, indy beauty, Lucobase, Mildison, OLIVA, PoxClin, and PROPYLESS brands; intimate care products under the HemoClin, Multi-Gyn, Multi-Mam, Pevaryl, Scheriproct, and Selexid brand names; and foot care products under the CCS, Cortimyk, Footner, Nailner, Pevaryl, and wortie brands. The company also provides pain, cough, and cold products under the Bronkyl, Dolerin, Ibux, Mollipect, Nazamer, nozoil, Paracet, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, and Kaleorid brands; and wellness products under the Flux, Allévo, Dosett, Dax, antibac, BAMSE, Betavivo, and Lactocare brands. The company sells its products through direct sales organisations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.
Top 1-year algo backtest: +227.67%
$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Karo Pharma AB has the following listings and related stock indices.
Stock: OMX: KARO wb_incandescent
Stock: FSX: KA6N wb_incandescent